Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Boxed safety warning The label for Camzyos does however include a boxed warning for worsening heart failure, which is tied to the mechanism of the drug in reducing LVEF and the workload on the ...

Mavacamten has since been approved in the US, Europe, and Japan under the Camzyos brand name as ... and potentially more if the label for the drug is extended to include non-obstructive HCM ...

Camzyos only comes as a brand-name drug. It’s not currently available in a generic version. A generic contains an exact copy of the active ingredient in a brand-name medication but tends to cost ...

Camzyos (mavacamten) is a prescription drug that works to treat obstructive hypertrophic cardiomyopathy (HCM) by relaxing your heart muscle, allowing it to pump blood more easily. Doctors ...

Camzyos (mavacamten), a first-in-class heart disease drug, was approved by the FDA on April 28, 2022 to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM), a genetic condition that causes ...